

Claros Diagnostics Named by MIT's *Technology Review* as one of the 50 Most Innovative Companies of 2011

Claros included with Novartis, Roche, IBM, Google, Apple, Facebook, Groupon and others on the second annual TR50 Most Innovative Companies list

WOBURN, Mass. – February 22, 2011 – Claros Diagnostics, a developer of novel point-of-care *in vitro* diagnostic systems, announced that the company was named by MIT's *Technology Review* to the TR50 list of The Most Innovative Companies of 2011 (found at <http://www.technologyreview.com/tr50/>).

“Being named next to technology giants such as Apple, Google, and Facebook and biomedical innovators including Novartis and Roche is an honor and recognition of the groundbreaking work being done by the team here at Claros,” said Michael J. Magliochetti, Ph.D., President and CEO of Claros. “We believe our technology will, for the first time, put complex laboratory testing literally in the palm of your hand, and truly change the way medicine is practiced.”

To select the TR50, the editors of *Technology Review* identify companies that are either leading their industries with an important new technology, disrupting an established market, or creating an entirely new market. The TR50 list includes public and private companies covering the Energy, Transportation, Computing and Communications, Web & Digital Media, Materials, and Biomedicine sectors.

The TR50 for 2011 is the second annual list of most innovative companies to appear in *Technology Review*. Claros was added to the list in 2011 for its innovations in microfluidic technology applied to point-of-care diagnostic test systems, while prominent companies including Adobe and Hulu were removed from the list.

About Claros Diagnostics' Point-of-care System

Claros Diagnostics' point-of-care system consists of disposable test cassettes and a small (desktop or handheld) analyzer, which delivers high performance quantitative laboratory blood test results with significant ease-of-use allowing the transition of complex immunoassays and other tests from the centralized reference laboratory to the point-of-care (bedside, physician's office, etc.). Attractive attributes of the technology include the ability to use a finger-stick of whole blood, automation of all assay steps, multiplexing, on-board controls, cost effectiveness and the delivery of results in minutes. The urology market has been the initial focus to validate the technology, while also serving as a bridge to other test panels for infectious disease, women's health, cardiology, companion diagnostics, and beyond, with applications in settings throughout the world.

About Technology Review, Inc.

Technology Review is an independent media company owned by the Massachusetts Institute of Technology (MIT). More than two million people around the globe read our publications in five languages and on a variety of digital and print platforms. We publish *Technology Review* magazine, the world's oldest technology magazine (established 1899); daily news, analysis, opinion, and video; and *Business Impact*, which explains how new technologies are transforming companies, disrupting markets, or creating entirely new industries. We also produce live events.

About Claros Diagnostics, Inc.

Claros Diagnostics, Inc. is creating innovative products to transition *in vitro* medical diagnostic tests from the laboratory to the point-of-care, such as a physician's office or bedside. Claros is a venture-financed company located in Woburn, MA.

www.clarosdx.com

Company Contact:

Claros Diagnostics, Inc.

Michael J. Magliochetti, Ph.D.

781-933-8010